Trial Profile

Multicenter, Prospective, Randomised and Comparative Study of AA Therapy and Early Administrating Enzalutamide in Participants With CRPC Previously Treated With CAB Therapy Using Bicalutamide

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Sep 2021 Results (data cut off: December 31, 2020) presented at the 116th Annual Meeting of the American Urological Association
04 Jun 2019 Results of a follow-up observational study presented at the 55th Annual Meeting of the American Society of Clinical Oncology
16 Feb 2019 Primary endpoint (Percentage of participants whose prostate specific antigen (PSA) decreased 50 percent or more at month 3) has been met as per results presented at the 2019 Genitourinary Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com